Growth Funding Delphinus has raised substantial growth capital (around $12M in 2023) and secured funding from Trinity Capital, signaling strong investor confidence and capacity for expansion, which creates opportunities for strategic partnerships, co-development, and channel expansion with larger healthcare partners.

Regulatory Validation SoftVue has FDA 510(k) clearance for diagnostic imaging, positioning the platform as a credible option in breast imaging. This regulatory standing can facilitate conversations with hospitals, imaging centers, and insurance providers seeking proven, non-radiation alternatives for breast diagnostics.

Clinical Leadership Recent leadership updates include a new Chief Commercial Officer appointment and a move by a former CMO to Mammogen, highlighting ongoing emphasis on clinical adoption, market access, and physician engagement, which bodes well for outreach to radiology departments and breast imaging specialists.

Recognition & Voice Technology Breakthrough designation from Premier in 2024 enhances credibility for procurement discussions, enabling accelerated pilots and demonstrations with health systems seeking innovative imaging solutions and potential reimbursements advantages.

Market Position With a specialty in dense breast imaging and a unique ring-transducer whole-breast tomography approach, Delphinus differentiates from conventional ultrasound, presenting a compelling value proposition for clinics serving high-dense-breast populations and for partnerships with radiology groups aiming to expand imaging portfolios.